Comparison of Subthreshold 532 nm Diode Micropulse Laser with Conventional Laser Photocoagulation in the Treatment of Non-Centre Involved Clinically Significant Diabetic Macular Edema
Language English Country Czech Republic Media print
Document type Comparative Study, Journal Article, Randomized Controlled Trial
PubMed
32422113
DOI
10.14712/18059694.2020.12
PII: am_2020063010025
Knihovny.cz E-resources
- Keywords
- 532 nm, conventional laser photocoagulation, diabetic macular edema, micropulse laser, subthreshold laser,
- MeSH
- Diabetic Retinopathy pathology physiopathology surgery MeSH
- Laser Coagulation methods MeSH
- Lasers, Semiconductor MeSH
- Middle Aged MeSH
- Humans MeSH
- Macular Edema pathology physiopathology surgery MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Visual Acuity MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
BACKGROUND: The aim of the study was to investigate the effect of the 532 nm (green) diode subthreshold micropulse laser (SML) in the treatment of non-centre involved clinically significant macular edema (CSME) in comparison to the conventional laser photocoagulation (CLP). METHODS: A total of 60 eyes of patients diagnosed with non-centre involved CSME were randomly divided into two groups. SML photocoagulation was performed in the first group (G1), while CLP in the second one (G2). Central macular thickness (CMT) and best corrected visual acuity (BCVA) were measured prior to treatment and at 3 and 6 months after intervention. RESULTS: G1 participants had significantly better CMT at 6 months after laser application (p = 0.04) compared to G2. Additionally, CMT in both groups was significantly lower 6 months after laser application in comparison to baseline values (G1: p < 0.001, G2: p = 0.002). Moreover, significant improvement was detected 6 months after SML in G1 regarding BCVA compared to values before laser treatment (p = 0.001). CONCLUSION: SML was more effective than CLP in reducing CMT and improving BCVA in patients with non-centre involved CSME. Therefore, it seems that SML can be a good substitute for CLP in DME treatment if confirmed in future studies.
References provided by Crossref.org